We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
UK pharma group says country’s chemistry prowess makes it a good source of molecules
First jab for respiratory syncytial virus powers sales at UK drugmaker
UK drugmaker reaches agreement in US over cases tied to allegations heartburn medicine causes cancer
Agreement is first of its kind in China for UK-based pharma group
Accenture legal team wins FT award for its work on taking risks with confidence
Scientists hail ‘entirely novel approach’ to controlling a disease that kills more than 600,000 a year
Drugmaker does not specify reason but forex shortage has put pressure on multinationals
Companies analysis from our sister publication
Drugmaker projects rise in revenue of up to 10% after consensus-beating second quarter
Deal avoids California trial over allegations that group’s medication caused cancer
Former GSK and Pfizer joint venture shines
Industry watchers say UK-listed rival AstraZeneca has a stronger pipeline and benefits from its oncology expertise
US regulators say drugmaker’s Xevudy fails to tackle most prevalent variants of coronavirus
Modest size of acquisition leaves the UK pharma group well positioned to make further bolt-on deals
UK pharma group agrees to buy Bellus Health in effort to strengthen pipeline
UK drugmaker’s shingles vaccine boosts sales while demand for Covid-related products falls
Sebastien de La Riviere’s move is latest in a number of high-profile departures inside activist’s London office
A greater focus on innovation should top the UK pharma chief executive’s agenda
Chief commercial officer Luke Miels looking at targets worth up to $2.5bn
Judge rules that scientific evidence provided by the claimants was flawed
US judge dismisses almost 2,500 lawsuits alleging links between heartburn medication and cancer
UK pharma group will continue to lag rivals until litigation risk subsides
UK drugmaker beats forecasts and ‘expects good momentum in 2023’
Drugmaker says new RSV shot appears more effective than rival Pfizer’s candidate
Newly listed consumer health group refuses indemnification requests related to heartburn drug
UK Edition
